Biocon Biologics Bengaluru facility gets EU GMP certification for Bevacizumab

Biocon Biologics Limited, a subsidiary of Biocon Limited, is a fully integrated global biosimilars organization. Biocon Biologics has eight commercialized products in global markets. The company has a portfolio of biosimilar assets, including insulins, monoclonal antibodies and conjugated recombinant proteins in therapeutic areas such as diabetology, oncology, immunology, and ophthalmology, which is one of the broadest and deepest biosimilar in the industry. Biocon Biologics has invested over USD 1 billion to date in R&D and global scale manufacturing and has end-to-end capabilities for producing drug substance, drug product and delivery devices across multiple sites in India and Malaysia. The company’s products are marketed globally through a hybrid commercial model with a combination of direct presence, strategic partnerships and distributor tie-ups.